检索

期
标题
作者
卷 95, 编号 4 (2023)
Applying of magnetic resonance tomography for assessment of cardiac remodeling and risk stratification in patients with pulmonary arterial hypertension
Shariya A., Martynyuk T., Shariya M., Ustyuzhanin D.
PDF
(Rus)
卷 92, 编号 3 (2020)
Socio-economic burden of pulmonary hypertension: relevance of assessment in Russia and the world
Zakiev V., Gvozdeva A., Martynyuk T.
PDF
(Rus)
卷 85, 编号 12 (2013)
Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension
Tsareva N.
卷 91, 编号 12 (2019)
A systematic review as a method of gathering scientific evidence into clinical guidelines: CHEST-2019 guideline for the therapy pulmonary arterial hypertension in adults
Shmalts A., Gorbachevsky S.
PDF
(Rus)
卷 92, 编号 12 (2020)
Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia
Shmalts A., Gorbachevsky S.
PDF
(Rus)
卷 90, 编号 3 (2018)
Combination therapy is a new standard for treatment of pulmonary arterial hypertension
Avdeev S., Tsareva N., Gaisin I.
PDF
(Rus)
卷 92, 编号 9 (2020)
The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
Gratsianskaya S., Valieva Z., Martynyuk T.
PDF
(Rus)
卷 93, 编号 9 (2021)
Evidence base for specific pulmonary vasodilators in adults with congenital heart disease
Shmalts A., Gorbachevsky S.
PDF
(Rus)
卷 90, 编号 4 (2018)
New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension
Martynyuk T., Nakonechnikov S., Chazova I.
PDF
(Rus)
卷 87, 编号 9 (2015)
Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan
Avdeev S.
卷 91, 编号 1 (2019)
Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry
Chazova I., Arkhipova O., Martynyuk T.
PDF
(Rus)
卷 89, 编号 9 (2017)
A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?
Tsareva N., Avdeev S., Neklyudova G.
PDF
(Rus)
卷 85, 编号 3 (2013)
First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study
Avdeev S., Tsareva N., Nekliudova G., Chuchalin A.
卷 91, 编号 12 (2019)
Evolution of pathogenetic therapy of pulmonary arterial hypertension
Chazova I., Yarovoy S., Danilov N.
PDF
(Rus)
卷 89, 编号 8 (2017)
Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
Valieva Z., Martynyuk T., Chazova I.
PDF
(Rus)
卷 91, 编号 9 (2019)
Risk stratification methods and their significance in pulmonary arterial hypertension
Avdeev S., Tsareva N.
PDF
(Rus)
卷 93, 编号 9 (2021)
Pulmonary arterial hypertension: achievements and realities of modern treatment, a look into the future
Martynyuk T., Chazova I.
PDF
(Rus)
卷 90, 编号 4 (2018)
Modern view on the place of riociguat in the treatment of pulmonary hypertension
Valieva Z., Taran I., Martynyuk T., Chazova I.
PDF
(Rus)
1 - 18 的 18 信息

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回（例如，隐含AND）
  • 使用OR结合多个检索词，便于查找含有这些检索词的文章，例如education OR research
  • 使用括号来创建更复杂的查询; 例如：archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如： "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如：online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语

##common.cookie##